<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35314906</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1530-9932</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
              <Day>21</Day>
            </PubDate>
          </JournalIssue>
          <Title>AAPS PharmSciTech</Title>
          <ISOAbbreviation>AAPS PharmSciTech</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Physical Stability of Felodipine and Its Recrystallization from an Amorphous Solid Dispersion Studied by NMR Relaxometry.</ArticleTitle>
        <Pagination>
          <StartPage>93</StartPage>
          <MedlinePgn>93</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1208/s12249-022-02234-8</ELocationID>
        <Abstract>
          <AbstractText>The <sup>1</sup>H nuclear magnetic resonance (NMR) relaxometry method was applied to investigate the physical stability of an active pharmaceutical ingredient (API) and, for the first time, its recrystallization process in an amorphous solid dispersion system (ASD). The ASD of felodipine and polyvinylpyrrolidone (PVP) was prepared using the solvent evaporation method in a mass ratio of 50:50. In the first stage of the study (250 days), the sample was stored at 0% relative humidity (RH). The recovery of magnetization was described by one-exponential function. In the second stage (300 days in 75% relative humidity), the recrystallization process of felodipine was studied, showing in the sample three components of equilibrium magnetization related to (i) crystalline felodipine, (ii) water, and (iii) felodipine and PVP remaining in the ASD. The study shows that the <sup>1</sup>H NMR relaxometry method is a very useful tool for analysing the composition of a three-phase system mixed at the molecular level and for the investigation of recrystallization process of API in amorphous solid dispersion system.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pajzderska</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-8096-7718</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medical Physics and Radiospectroscopy, Faculty of Physics, Adam Mickiewicz University, Uniwersytetu Poznańskiego 2, 61-614, Poznan, Poland. apajzder@amu.edu.pl.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mielcarek</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Inorganics and Analytical Chemistry, Poznań University of Medical Sciences, Grunwaldzka 6, 60-780, Poznan, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wąsicki</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Physics and Radiospectroscopy, Faculty of Physics, Adam Mickiewicz University, Uniwersytetu Poznańskiego 2, 61-614, Poznan, Poland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NanoBioMedical Centre, Adam Mickiewicz University, Wszechnicy Piastowskiej 3, 61-614, Poznan, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>AAPS PharmSciTech</MedlineTA>
        <NlmUniqueID>100960111</NlmUniqueID>
        <ISSNLinking>1530-9932</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>FZ989GH94E</RegistryNumber>
          <NameOfSubstance UI="D011205">Povidone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>OL961R6O2C</RegistryNumber>
          <NameOfSubstance UI="D015736">Felodipine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003460" MajorTopicYN="N">Crystallization</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004355" MajorTopicYN="N">Drug Stability</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015736" MajorTopicYN="Y">Felodipine</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011205" MajorTopicYN="Y">Povidone</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">PVP</Keyword>
        <Keyword MajorTopicYN="N">amorphous solid dispersion</Keyword>
        <Keyword MajorTopicYN="N">felodipine</Keyword>
        <Keyword MajorTopicYN="N">physical stability</Keyword>
        <Keyword MajorTopicYN="N">recrystallization</Keyword>
        <Keyword MajorTopicYN="N">relaxometry</Keyword>
        <Keyword MajorTopicYN="N">time-domain NMR</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>5</Hour>
          <Minute>38</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35314906</ArticleId>
        <ArticleId IdType="doi">10.1208/s12249-022-02234-8</ArticleId>
        <ArticleId IdType="pii">10.1208/s12249-022-02234-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm. 2011;42:1–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2011.08.032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Renuka, Singh SK, Gulati M, Narang R. Stable amorphous binary systems of glipizide and atorvastatin powders with enhanced dissolution profiles: formulation and characterization. Pharm Dev Technol. 2017;22:13–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26708555</ArticleId>
            <ArticleId IdType="doi">10.3109/10837450.2015.1125921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takagi T, Ramachandran C, Bermejo M, Yamashita S, Yu LX, Amidon GL. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan Mol Pharm. 2006;3:631-643.</Citation>
        </Reference>
        <Reference>
          <Citation>Löbenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm. 2000;50:3–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10840189</ArticleId>
            <ArticleId IdType="doi">10.1016/S0939-6411(00)00091-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res. 2000;17:397–403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10870982</ArticleId>
            <ArticleId IdType="doi">10.1023/A:1007516718048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu B, Theil F, Lehmkemper K, Gessner D, Li Y, Lishaut H. Crystallization risk assessment of amorphous solid dispersions by physical shelf-life modeling: a practical approach. Mol Pharm. 2001;18:2428–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.molpharmaceut.1c00270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, Pairaudeau G, Pennie WD, Pickett SD, Wang J, Wallace O, Weir A. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov. 2015;14:475–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26091267</ArticleId>
            <ArticleId IdType="doi">10.1038/nrd4609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palpandi P, Bulusu R, Kommineni N, Khan W, Singh M. Amorphous solid dispersions: an update for preparation, characterization, mechanism on bioavailability, stability, regulatory considerations and marketed products. Int J Pharm. 2020;586:1195603.</Citation>
        </Reference>
        <Reference>
          <Citation>Schittny A, Huwyler J, Puchkov M. Mechanisms of increased bioavailability through amorphous solid dispersions: a review. Drug Delivery. 2020;27:110–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31885288</ArticleId>
            <ArticleId IdType="doi">10.1080/10717544.2019.1704940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pandi P, Bulusu R, Kommineni N, Khan W, Singh M. Amorphous solid dispersions: an update for preparation, characterization, mechanism on bioavailability, stability, regulatory considerations and marketed products. Int J Pharm. 2020;586:119560.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32565285</ArticleId>
            <ArticleId IdType="pmc">8691091</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2020.119560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang S, Williams RO. Effects of the preparation process on the properties of amorphous solid dispersions. AAPS PharmSciTech. 2018;19:1971–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28924730</ArticleId>
            <ArticleId IdType="doi">10.1208/s12249-017-0861-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konno H, Taylor LS. Ability of different polymers to inhibit the crystallization of amorphous felodipine in the presence of moisture. Pharm Res. 2008;25:969–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17520180</ArticleId>
            <ArticleId IdType="doi">10.1007/s11095-007-9331-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor LS, Braun DE, Steed JW. Crystals and crystallization in drug delivery design. Mol Pharm. 2021;18:751–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33594892</ArticleId>
            <ArticleId IdType="doi">10.1021/acs.molpharmaceut.0c01157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rumondor ACF, Marsac PJ, Stanford LA. Taylor LS Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture. Mol Pharm. 2009;6:1492–505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19634917</ArticleId>
            <ArticleId IdType="doi">10.1021/mp900050c</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bikiaris D, Papageorgiou GZ, Stergiou A, Pavlidou E, Karavas E, Kanaze F, Georgarakis M. Physicochemical studies on solid dispersions of poorly water-soluble drugs: evaluation of capabilities and limitations of thermal analysis techniques. Thermochim Acta. 2005;439:58–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tca.2005.09.011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wegiel LA, Mauer LJ, Edgar KJ, Taylor LS. Crystallization of amorphous solid dispersions of resveratrol during preparation and storage - impact of different polymers. J Pharm Sci. 2013;102:171–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23132686</ArticleId>
            <ArticleId IdType="doi">10.1002/jps.23358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Zhang L, Ma D, Tang X, Zhang Y, Yin T, Gou J, Wang Y, He H. Characterizing and exploring the differences in dissolution and stability between crystalline solid dispersion and amorphous solid dispersion. AAPS PharmSciTech. 2020;21:262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32975680</ArticleId>
            <ArticleId IdType="doi">10.1208/s12249-020-01802-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chmiel K, Knapik-Kowalczuk J, Jurkiewicz K, Sawicki W, Jachowicz R, Paluch M. A new method to identify physically stable concentration of amorphous solid dispersions (I): case of flutamide + kollidon VA64. Mol Pharm. 2017;14:3370–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28787567</ArticleId>
            <ArticleId IdType="doi">10.1021/acs.molpharmaceut.7b00382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paudel A, Geppi M, Mooter G. Structural and dynamic properties of amorphous solid dispersions: the role of solid-state nuclear magnetic resonance spectroscopy and relaxometry. J Pharm Sci. 2014;103:2635–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24715618</ArticleId>
            <ArticleId IdType="doi">10.1002/jps.23966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mollica G, Geppi M, Pignatello R, Veracini CA. Molecular properties of flurbiprofen and its solid dispersions with Eudragit RL100 studied by high- and low-resolution solid-state nuclear magnetic resonance. Pharm Res. 2006;23:2129–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16952004</ArticleId>
            <ArticleId IdType="doi">10.1007/s11095-006-9044-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu X, Huang C, Lowinger MB, Yang F, Xu W, Brown CW, Hesk D, Koynov A, Schenck L, Su Y. Molecular interactions in posaconazole amorphous solid dispersions from two-dimensional solid-state NMR spectroscopy. Mol Pharm. 2019;16:2579–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31021639</ArticleId>
            <ArticleId IdType="doi">10.1021/acs.molpharmaceut.9b00174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pham TN, Watson SA, Edwards AJ, Chavda M, Clawson JS, Strohmeier M, Vogt FG. Analysis of amorphous solid dispersions using 2D solid-state NMR and <sup>1</sup>H T<sub>1</sub> relaxation measurements. Mol Pharm. 2010;7:1667–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20681586</ArticleId>
            <ArticleId IdType="doi">10.1021/mp100205g</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li M, Xu W, Su Y. Solid-state NMR spectroscopy in pharmaceutical sciences. Trends Anal Chem. 2021;135:116152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trac.2020.116152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aso Y, Yoshioka S, Miyazaki T, Kawanishi T, Tanaka K, Kitamura S, Takakura A, Hayashi T, Muranushi N. Miscibility of nifedipine and hydrophilic polymers as measured by <sup>1</sup>H-NMR spin-lattice relaxation. Chem Pharm Bull. 2007;55:1227–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1248/cpb.55.1227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tishmack PA, Bugay DE, Byrn SR. Solid-state nuclear magnetic resonance spectroscopy in pharmaceutical applications. J Pharm Sci. 2003;92:441–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12587108</ArticleId>
            <ArticleId IdType="doi">10.1002/jps.10307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geppi M, Borsacchi S, Carignani E. Study of disorder by solid-state NMR spectroscopy. In: Disordered Pharmaceutical Materials, M. Descamps (Ed.); 2016.</Citation>
        </Reference>
        <Reference>
          <Citation>Geppi M, Mollica G, Borsacchi S, Veracini CA, Solid-state NMR studies of pharmaceutical systems. Appl Spectr Reviews 2008;43:202–302</Citation>
        </Reference>
        <Reference>
          <Citation>Carignani E, Geppi LM, Combarieu Em Dorsacchi S. Solid state NMR of the mixing degree between Ginkgo biloba extract and a soy-lecithin-phosphatidylserine in a composite prepared by the phytosome method. Chem Africa. 2020;3:717–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s42250-020-00165-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okada K, Hirai D, Kumada S, Kosugi A, Hayashi Y, Onuki Y. <sup>1</sup>H NMR relaxation study to evaluate the crystalline state of active pharmaceutical ingredients containing solid dosage forms using time domain NMR. J Pharm Sci 2019;108:451-456.</Citation>
        </Reference>
        <Reference>
          <Citation>Stueber D, Jehle S. Quantitative component analysis of solid mixtures by analyzing time domain <sup>1</sup>H and <sup>19</sup>F T<sub>1</sub> saturation recovery curves (qSRC), J Pharm Sci 2017;106:1828-1838.</Citation>
        </Reference>
        <Reference>
          <Citation>Chattoraj S, Bhugra C, Li ZJ, Sun C. Effect of heating rate and kinetic model selection on activation energy of nonisothermal crystallization of amorphous felodipine. J Pharm Sci. 2014;103:3950–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25351553</ArticleId>
            <ArticleId IdType="doi">10.1002/jps.24204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Praveen C, Arthanareeswari M, Ravikiran A, Kamaraj P, Pavan KV. Kinetic studied on crystallization process of amorphous Vilazodone hydrochloride. Int J Pharm Sci. 2014;6:630–5.</Citation>
        </Reference>
        <Reference>
          <Citation>Crowley KJ, Zografi G. The effect of low concentrations of molecularly dispersed poly(vinylpyrrolidone) on indomethacin crystallization from the amorphous state. Pharm Res. 2003;20:1417–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14567636</ArticleId>
            <ArticleId IdType="doi">10.1023/A:1025706110520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu L, Jona J, Nagapudi K, Wu T. Fast surface crystallization of amorphous griseofulvin below Tg. Pharm Res. 2010;27:1558–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20414704</ArticleId>
            <ArticleId IdType="doi">10.1007/s11095-010-0140-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kestur US, Ivanesivic I, Alonzo DE, Taylor LS. Influence of particle size on the crystallization kinetics of amorphous felodipine powders. Powder Technol. 2013;236:197–204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.powtec.2012.02.010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marsac PJ, Konno H, Taylor LS. A comparison of the physical stability of amorphous felodipine and nifedipine systems. Pharm Res. 2006;23:2306–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16927182</ArticleId>
            <ArticleId IdType="doi">10.1007/s11095-006-9047-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marsac PJ, Konno H, Rumondor ACF, Taylor LS. Recrystallization of nifedipine and felodipine from amorphous molecular level solid dispersions containing poly(vinylpyrrolidone) and sorbed water. Pharm Res. 2008;25:647–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17846870</ArticleId>
            <ArticleId IdType="doi">10.1007/s11095-007-9420-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu L, Wong L, Yu L. Surface-enhanced crystallization of amorphous nifedipine. Mol Pharm. 2008;5:921–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19434917</ArticleId>
            <ArticleId IdType="doi">10.1021/mp8000638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kestur US, Taylor LS. Role of polymer chemistry in influencing crystal growth rates from amorphous felodipine. Cryst Eng Comm. 2010;12:2390–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/c001905d</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ricarte RG, Lodge TP, Hillmyer MA. Detection of pharmaceutical drug crystallites in solid dispersions by transmission electron microscopy. Mol Pharm. 2015;12:983–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25699402</ArticleId>
            <ArticleId IdType="doi">10.1021/mp500682x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alonzo DE, Zhang GGZ, Zhou D, Gao Y, Taylor LS. Understanding the behavior of amorphous pharmaceutical systems during dissolution. Pharm Res. 2010;27:608–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20151181</ArticleId>
            <ArticleId IdType="doi">10.1007/s11095-009-0021-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaminska E, Tarnacka M, Wlodarczyk P, Jurkiewicz K, Kolodziejczyk K, Dulski M, Haznar-Garbacz D, Hawelek L, Kaminski K, Wlodarczyk A, Paluch M. Studying the impact of modified saccharides on the molecular dynamics and crystallization tendencies of model api nifedipine. Mol Pharm. 2015;12:3007–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26101945</ArticleId>
            <ArticleId IdType="doi">10.1021/acs.molpharmaceut.5b00271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sibik J, Löbmann K, Rades T, Zeitler JA. Predicting crystallization of amorphous drugs with terahertz spectroscopy. Mol Pharm. 2015;12:3062–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26090554</ArticleId>
            <ArticleId IdType="doi">10.1021/acs.molpharmaceut.5b00330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pajzderska A, Fojud Z, Jarek M, Wasicki J. NMR relaxometry In the investigation of the kinetics of the recrystallization of felodipine. Powder Technol. 2019;347:35–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.powtec.2019.02.041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pajzderska A, Wasicki J. NMR relaxometry in a investigation of the kinetics of the recrystallization of a three-phase system. Int J Pharm. 2021;605:120800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34133972</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2021.120800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rumondor ACF, Stanford LA, Taylor LS. Effects of polymer type and storage relative humidity on the kinetics of felodipine crystallization from amorphous solid dispersions. Pharm Res. 2009;26:2599–606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19806435</ArticleId>
            <ArticleId IdType="doi">10.1007/s11095-009-9974-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang XC, Pikal MJ, Taylor LS. A spectroscopic investigation of hydrogen bond patterns in crystalline and amorphous phases in dihydropyridine calcium channel blockers. Pharm Res. 2002;19:477–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12033383</ArticleId>
            <ArticleId IdType="doi">10.1023/A:1015147729564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pajzderska A, Drużbicki K, Gonzalez MA, Jenczyk J, Mielcarek J, Wąsicki J. Diversity of methyl group dynamics in felodipine: a DFT supported NMR and neutron scattering study. Cryst Eng Comm. 2018;20:7371–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C8CE01605D</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pajzderska A, Jenczyk J, Embs JP, Wasicki J. Exploring molecular reorientations in amorphous and recrystallized felodipine at the microscopic level. RSC Adv. 2020;10:37346–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/D0RA07266D</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konno H, Taylor LS. Ability of different polymers to inhibit the crystallization of amorphous, felodipine in the presence of moisture. Pharm Res. 2008;25:969–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17520180</ArticleId>
            <ArticleId IdType="doi">10.1007/s11095-007-9331-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rumondor ACF, Ivanisevic I, Bates S, Alonzo DE, Taylor LS. Evaluation of drug-polymer miscibility in amorphous solid dispersion systems. Pharm Res. 2009;26:2523–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19771495</ArticleId>
            <ArticleId IdType="doi">10.1007/s11095-009-9970-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qi S, Belton P, Nollenberger K, Clayden N, Reading M, Craig DQM. Characterisation and prediction of phase separation in hot-melt extruded solid dispersions: a thermal, microscopic and NMR relaxometry study. Pharm Res. 2010;27:1869–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20585845</ArticleId>
            <ArticleId IdType="doi">10.1007/s11095-010-0185-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ivanisevic I. Physical stability studies of miscible amorphous solid dispersions. J Pharm Sci. 2010;99:4005–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20533553</ArticleId>
            <ArticleId IdType="doi">10.1002/jps.22247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luebbert C, Klanke C, Sadowski G. Investigating phase separation in amorphous solid dispersions via Raman mapping. Int J Pharm. 2017;535:245–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29133204</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2017.11.014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luebbert C, Wessner M, Sadowski G. Mutual impact of phase separation/crystallization and water sorption in amorphous solid dispersions. Mol Pharm. 2018;15:669–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29309155</ArticleId>
            <ArticleId IdType="doi">10.1021/acs.molpharmaceut.7b01076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarpal K, Delaney S, Zhang GGZ, Munson EJ. Phase behavior of amorphous solid dispersions of felodipine: homogeneity and drug-polymer interactions. Mol Pharm. 2019;16:4836–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31682129</ArticleId>
            <ArticleId IdType="doi">10.1021/acs.molpharmaceut.9b00731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ueda K, Okada H, Zhao Z, Higashi K, Moribe K. Application of solid-state <sup>13</sup>C relaxation time to prediction of the recrystallization inhibition strength of polymers on amorphous felodipine at low polymer loading. Int J Pharm. 2020;581:119300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32268185</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2020.119300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baghel S, Cathcart H, O’Reilly NJ. Polymeric amorphous solid dispersions: a review of amorphization, crystallization, stabilization, solid-state characterization, aqueous solubilization of biopharmaceutical classification system class II drugs. J Pharm Sci. 2016;105:2527–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26886314</ArticleId>
            <ArticleId IdType="doi">10.1016/j.xphs.2015.10.008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gordon M, Taylor LS. Ideal copolymers and the second-order transitions of synthetic rubbers. I. Non-crystalline copolymers. J Appl Chem. 1652;2:493–500.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jctb.5010020901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Powles JG, Mansfield P. Double-pulse nuclear resonance transients in solids. Phys Lett. 1962;2:58–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0031-9163(62)90147-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Powles JG, Strange JH. Zero time resolution nuclear magnetic resonance transients in solids. Proc Phys Soc. 1963;82:6–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1088/0370-1328/82/1/303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>PeakFit-Jandel Scientific Software, San Rafael, CA</Citation>
        </Reference>
        <Reference>
          <Citation>Schmidt-Rohr K. Spiess HW. London: Multidimensional solid-state N.M.R. and polymers Academic Press Limited; 1994.</Citation>
        </Reference>
        <Reference>
          <Citation>Guo M. Solid-state high-resolution NMR studies on the miscibility of polymer blends. Trends Polym Sci. 1996;7:238–44.</Citation>
        </Reference>
        <Reference>
          <Citation>Clauss J, Schmidt-Rohr K, Spiess HW. Determination of domain size in heterogeneous polymers by solid-state NMR. Acta Polym. 1993;44:1–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/actp.1993.010440101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spiegel S, Schmidt-Rohr K, Boeffel C, Spiess HW. <sup>1</sup>H spin diffusion coefficients of highly mobile polymers. Polymer. 1993;34:4566–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0032-3861(93)90166-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qi S, Moffat JG, Yang Z. Early stage phase separation in pharmaceutical solid dispersion thin films under high humidity: improved spatial understanding using probe-based thermal and spectroscopic nanocharacterization methods. Mol Pharm. 2013;10:918–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23320617</ArticleId>
            <ArticleId IdType="doi">10.1021/mp300557q</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
